CA2151409C - Formulation pour stabiliser les gammaglobulines humaines - Google Patents

Formulation pour stabiliser les gammaglobulines humaines Download PDF

Info

Publication number
CA2151409C
CA2151409C CA 2151409 CA2151409A CA2151409C CA 2151409 C CA2151409 C CA 2151409C CA 2151409 CA2151409 CA 2151409 CA 2151409 A CA2151409 A CA 2151409A CA 2151409 C CA2151409 C CA 2151409C
Authority
CA
Canada
Prior art keywords
formulation
rho
human
solution
immunoglobulins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA 2151409
Other languages
English (en)
Other versions
CA2151409A1 (fr
Inventor
Juan Carlos Rodriguez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PURISSIMUS SA
Original Assignee
PURISSIMUS S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PURISSIMUS S.A. filed Critical PURISSIMUS S.A.
Publication of CA2151409A1 publication Critical patent/CA2151409A1/fr
Application granted granted Critical
Publication of CA2151409C publication Critical patent/CA2151409C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CA 2151409 1995-05-05 1995-06-09 Formulation pour stabiliser les gammaglobulines humaines Expired - Fee Related CA2151409C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AR331,960 1995-05-05
AR33196095 1995-05-05

Publications (2)

Publication Number Publication Date
CA2151409A1 CA2151409A1 (fr) 1996-11-06
CA2151409C true CA2151409C (fr) 2000-08-15

Family

ID=3478952

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2151409 Expired - Fee Related CA2151409C (fr) 1995-05-05 1995-06-09 Formulation pour stabiliser les gammaglobulines humaines

Country Status (1)

Country Link
CA (1) CA2151409C (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6914998A (en) * 1997-04-07 1998-10-30 Cangene Corporation Intravenous immune globulin formulation containing a non-ionic surface active agent with improved pharmacokinetic properties
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof

Also Published As

Publication number Publication date
CA2151409A1 (fr) 1996-11-06

Similar Documents

Publication Publication Date Title
EP1084147B1 (fr) Procede de production d'immunoglobulines destinees a une administration intraveineuse et d'autres produits d'immunoglobulines
US6281336B1 (en) Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
EP0073371B1 (fr) Globuline de sérum immunisant injectable par voie intraveineuse et son procédé de préparation
US4499073A (en) Intravenously injectable immune serum globulin
US6485932B1 (en) Composition comprising immunoglobulin
US5122373A (en) Immunoglobulin-g-containing fraction
CA1331135C (fr) Solutions injectables de _-globuline
JPH0378373B2 (fr)
JPS5822085B2 (ja) 静注用ガンマ・グロブリン製剤
AU709608B2 (en) Preparation of virally inactivated intravenously injectable immune serum globulin
EP0085747B2 (fr) Immunoglobuline humaine pour administration intraveineuse et son procédé de préparation
Mollison et al. Suppression of primary Rh immunization by passively‐administered antibody. Experiments in volunteers
CA2151409C (fr) Formulation pour stabiliser les gammaglobulines humaines
Delmer et al. Acquired von Willebrand disease: correction of hemostatic defect by high‐dose intravenous immunoglobulins
US4886758A (en) Method of determining incompatibility-reaction-causing substances in blood products as well as a method of inactivating said incompatibility-reaction-causing substances
Salama et al. Use of Rh antibodies in the treatment of autoimmune thrombocytopenia
Pavlovsky et al. Use of factor VIII in the treatment of hemophilia
JP2838166B2 (ja) 第▲ｖｉｉｉ▼因子阻害剤産生の抑制のための医薬組成物および方法
Tomono et al. A new intact immunoglobulin for intravenous use stabilized by chemically modified gelatin derivatives
JPH10504310A (ja) 生物学的に活性な化合物で患者を治療する方法
Karger PL MOLLISON, NC HUGHES-JONES, MARGARET LINDSAY and JANE WESSELY
Specht et al. Management of Chronic Idiopathic Thrombocytopenia (Werlhof’s Disease) by Partial Splenic Resection—An Alternative to Splenectomy in Childhood?
EP0155235A2 (fr) Traitement de la conjonctivite vernale
CS221172B1 (cs) SJaLflzovený roztok hidakéhsi gamagksbalínu o nízkej koncentrácii bieikovín

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed